Anti-depressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression. According to WHO almost 350 million people worldwide were affected with depression in 2016. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression. The global anti-depressant drugs market was valued at $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023.
Key Benefits
By Depression Disorder
Key Benefits
- This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
- In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
By Depression Disorder
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-norepinephrine reuptake Inhibitors
- Monoamine oxidase inhibitors
- Serotonin antagonist and reuptake inhibitors
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. MARKET SHARE ANALYSIS
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in Prevalence of Depression
3.5.1.2. Rise in Geriatric Population
3.5.1.3. Increase in Awareness
3.5.2. Restrains
3.5.2.1. Non-Pharmacological Therapies Preferred Over Pharmacological Therapies
3.5.2.2. Poor Efficacy and Safety Profiles
3.5.2.3. Patent Expiry of Antidepressants leading to Weak Pipeline
3.5.3. Opportunities
3.5.3.1. Emergence of Novel Multimodal Therapies
CHAPTER 4: ANTI-DEPRESSANT DRUGS MARKET BY DEPRESSIVE DISORDER
4.1. OVERVIEW
4.1.1. Market Size and Forecast
4.2. MAJOR DEPRESSIVE DISORDER
4.2.1. Key Market Trends & Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. OBSESSIVE-COMPULSIVE DISORDER
4.3.1. Key Market Trends & Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. GENERALIZED ANXIETY DISORDER
4.4.1. Key Market Trends & Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country
4.5. PANIC DISORDER
4.5.1. Key Market Trends & Opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country
4.6. OTHERS
4.6.1. Key Market Trends & Opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country
CHAPTER 5: ANTI-DEPRESSANT DRUGS MARKET BY PRODUCT TYPE
5.1. OVERVIEW
5.1.1. Market Size and Forecast
5.2. TRICYCLIC ANTIDEPRESSANTS
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country
5.4. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
5.4.1. Market Size and Forecast
5.4.2. Market Analysis, by Country
5.5. MONOAMINE OXIDASE INHIBITORS
5.5.1. Market Size and Forecast
5.5.2. Market Analysis, by Country
5.6. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS
5.6.1. Market Size and Forecast
5.6.2. Market Analysis, by Country
5.7. OTHERS
5.7.1. Market Size and Forecast
5.7.2. Market Analysis, by Country
CHAPTER 6: ANTI-DEPRESSANT DRUGS MARKET BY GEOGRAPHY
6.1. OVERVIEW
6.1.1. Market Size and Forecast
6.2. NORTH AMERICA
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Depressive Disorder
6.2.3. Market Size and Forecast, by product type
6.2.4. Market Analysis, by Country
6.2.4.1. U.S. Market Size and Forecast, by Depressive Disorder
6.2.4.2. U.S. Market Size and Forecast, by product type
6.2.4.3. Canada Market Size and Forecast, by Depressive Disorder
6.2.4.4. Canada Market Size and Forecast, by Product Type
6.2.4.5. Mexico Market Size and Forecast, by Depressive Disorder
6.2.4.6. Mexico Market Size and Forecast, by Product Type
6.3. EUROPE
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Depressive Disorder
6.3.3. Market Size and Forecast, by Product Type
6.3.4. Market Analysis, by Country
6.3.4.1. Germany Market Size and Forecast, by Depressive Disorder
6.3.4.2. Germany Market Size and Forecast, by Product Type
6.3.4.3. France Market Size and Forecast, by Depressive Disorder
6.3.4.4. France Market Size and Forecast, by Product Type
6.3.4.5. UK Market Size and Forecast, by Depressive Disorder
6.3.4.6. UK Market Size and Forecast, by Product Type
6.3.4.7. Italy Market Size and Forecast, by Depressive Disorder
6.3.4.8. Italy Market Size and Forecast, by Product Type
6.3.4.9. Spain Market Size and Forecast, by Depressive Disorder
6.3.4.10. Spain Market Size and Forecast, by Product Type
6.3.4.11. Rest of Europe Market Size and Forecast, by Depressive Disorder
6.3.4.12. Rest of Europe Market Size and Forecast, by Product Type
6.4. ASIA-PACIFIC
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Depressive Disorder
6.4.3. Market Size and Forecast, by Product Type
6.4.4. Market Analysis, by Country
6.4.4.1. Japan Market Size and Forecast, by Depressive Disorder
6.4.4.2. Japan Market Size and Forecast, by Product Type
6.4.4.3. China Market Size and Forecast, by Depressive Disorder
6.4.4.4. China Market Size and Forecast, by Product Type
6.4.4.5. Australia Market Size and Forecast, by Depressive Disorder
6.4.4.6. Australia Market Size and Forecast, by Product Type
6.4.4.7. India Market Size and Forecast, by Depressive Disorder
6.4.4.8. India Market Size and Forecast, by Product Type
6.4.4.9. South Korea Market Size and Forecast, by Depressive Disorder
6.4.4.10. South Korea Market Size and Forecast, by Product Type
6.4.4.11. Rest of Asia-Pacific Market Size and Forecast, by Depressive Disorder
6.4.4.12. Rest of Asia-Pacific Market Size and Forecast, by Product Type
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Depressive Disorder
6.5.3. Market Size and Forecast, by Product Type
6.5.4. Market Analysis, by Country
6.5.4.1. Brazil Market Size and Forecast, by Depressive Disorder
6.5.4.2. Brazil Market Size and Forecast, by Product Type
6.5.4.3. Saudi Arabia Market Size and Forecast, by Depressive Disorder
6.5.4.4. Saudi Arabia Market Size and Forecast, by Product Type
6.5.4.5. South Africa Market Size and Forecast, by Depressive Disorder
6.5.4.6. South Africa Market Size and Forecast, by Product Type
6.5.4.7. Rest of LAMEA Market Size and Forecast, by Depressive Disorder
6.5.4.8. Rest of LAMEA Market Size and Forecast, by Product Type
CHAPTER 7: COMPANY PROFILES
7.1. ALKERMES PLC
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance
7.2. ALLERGAN PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. BRISTOL MYERS SQUIBB COMPANY
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Business performance
7.4. ELI LILLY AND COMPANY
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.5. GLAXOSMITHKLINE INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.6. H. LUNDBECK A/S
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Business performance
7.6.4. Key strategic moves and developments
7.7. MERCK INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.8. PFIZER INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.10. TAKEDA PHARMACEUTICAL INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Business performance
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. MARKET SHARE ANALYSIS
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in Prevalence of Depression
3.5.1.2. Rise in Geriatric Population
3.5.1.3. Increase in Awareness
3.5.2. Restrains
3.5.2.1. Non-Pharmacological Therapies Preferred Over Pharmacological Therapies
3.5.2.2. Poor Efficacy and Safety Profiles
3.5.2.3. Patent Expiry of Antidepressants leading to Weak Pipeline
3.5.3. Opportunities
3.5.3.1. Emergence of Novel Multimodal Therapies
CHAPTER 4: ANTI-DEPRESSANT DRUGS MARKET BY DEPRESSIVE DISORDER
4.1. OVERVIEW
4.1.1. Market Size and Forecast
4.2. MAJOR DEPRESSIVE DISORDER
4.2.1. Key Market Trends & Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. OBSESSIVE-COMPULSIVE DISORDER
4.3.1. Key Market Trends & Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. GENERALIZED ANXIETY DISORDER
4.4.1. Key Market Trends & Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country
4.5. PANIC DISORDER
4.5.1. Key Market Trends & Opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country
4.6. OTHERS
4.6.1. Key Market Trends & Opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country
CHAPTER 5: ANTI-DEPRESSANT DRUGS MARKET BY PRODUCT TYPE
5.1. OVERVIEW
5.1.1. Market Size and Forecast
5.2. TRICYCLIC ANTIDEPRESSANTS
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country
5.4. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
5.4.1. Market Size and Forecast
5.4.2. Market Analysis, by Country
5.5. MONOAMINE OXIDASE INHIBITORS
5.5.1. Market Size and Forecast
5.5.2. Market Analysis, by Country
5.6. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS
5.6.1. Market Size and Forecast
5.6.2. Market Analysis, by Country
5.7. OTHERS
5.7.1. Market Size and Forecast
5.7.2. Market Analysis, by Country
CHAPTER 6: ANTI-DEPRESSANT DRUGS MARKET BY GEOGRAPHY
6.1. OVERVIEW
6.1.1. Market Size and Forecast
6.2. NORTH AMERICA
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Depressive Disorder
6.2.3. Market Size and Forecast, by product type
6.2.4. Market Analysis, by Country
6.2.4.1. U.S. Market Size and Forecast, by Depressive Disorder
6.2.4.2. U.S. Market Size and Forecast, by product type
6.2.4.3. Canada Market Size and Forecast, by Depressive Disorder
6.2.4.4. Canada Market Size and Forecast, by Product Type
6.2.4.5. Mexico Market Size and Forecast, by Depressive Disorder
6.2.4.6. Mexico Market Size and Forecast, by Product Type
6.3. EUROPE
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Depressive Disorder
6.3.3. Market Size and Forecast, by Product Type
6.3.4. Market Analysis, by Country
6.3.4.1. Germany Market Size and Forecast, by Depressive Disorder
6.3.4.2. Germany Market Size and Forecast, by Product Type
6.3.4.3. France Market Size and Forecast, by Depressive Disorder
6.3.4.4. France Market Size and Forecast, by Product Type
6.3.4.5. UK Market Size and Forecast, by Depressive Disorder
6.3.4.6. UK Market Size and Forecast, by Product Type
6.3.4.7. Italy Market Size and Forecast, by Depressive Disorder
6.3.4.8. Italy Market Size and Forecast, by Product Type
6.3.4.9. Spain Market Size and Forecast, by Depressive Disorder
6.3.4.10. Spain Market Size and Forecast, by Product Type
6.3.4.11. Rest of Europe Market Size and Forecast, by Depressive Disorder
6.3.4.12. Rest of Europe Market Size and Forecast, by Product Type
6.4. ASIA-PACIFIC
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Depressive Disorder
6.4.3. Market Size and Forecast, by Product Type
6.4.4. Market Analysis, by Country
6.4.4.1. Japan Market Size and Forecast, by Depressive Disorder
6.4.4.2. Japan Market Size and Forecast, by Product Type
6.4.4.3. China Market Size and Forecast, by Depressive Disorder
6.4.4.4. China Market Size and Forecast, by Product Type
6.4.4.5. Australia Market Size and Forecast, by Depressive Disorder
6.4.4.6. Australia Market Size and Forecast, by Product Type
6.4.4.7. India Market Size and Forecast, by Depressive Disorder
6.4.4.8. India Market Size and Forecast, by Product Type
6.4.4.9. South Korea Market Size and Forecast, by Depressive Disorder
6.4.4.10. South Korea Market Size and Forecast, by Product Type
6.4.4.11. Rest of Asia-Pacific Market Size and Forecast, by Depressive Disorder
6.4.4.12. Rest of Asia-Pacific Market Size and Forecast, by Product Type
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Depressive Disorder
6.5.3. Market Size and Forecast, by Product Type
6.5.4. Market Analysis, by Country
6.5.4.1. Brazil Market Size and Forecast, by Depressive Disorder
6.5.4.2. Brazil Market Size and Forecast, by Product Type
6.5.4.3. Saudi Arabia Market Size and Forecast, by Depressive Disorder
6.5.4.4. Saudi Arabia Market Size and Forecast, by Product Type
6.5.4.5. South Africa Market Size and Forecast, by Depressive Disorder
6.5.4.6. South Africa Market Size and Forecast, by Product Type
6.5.4.7. Rest of LAMEA Market Size and Forecast, by Depressive Disorder
6.5.4.8. Rest of LAMEA Market Size and Forecast, by Product Type
CHAPTER 7: COMPANY PROFILES
7.1. ALKERMES PLC
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance
7.2. ALLERGAN PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. BRISTOL MYERS SQUIBB COMPANY
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Business performance
7.4. ELI LILLY AND COMPANY
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.5. GLAXOSMITHKLINE INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.6. H. LUNDBECK A/S
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Business performance
7.6.4. Key strategic moves and developments
7.7. MERCK INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.8. PFIZER INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.10. TAKEDA PHARMACEUTICAL INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Business performance
LIST OF TABLES
TABLE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 02. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 03. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 04. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR PANIC DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 06. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 08. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 09. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER PRODUCT TYPE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 14. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 19. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 20. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 21. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 22. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 23. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 24. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 25. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 26. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 28. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 29. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 30. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 31. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 32. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 33. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 34. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 35. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 36. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 37. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 38. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 39. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 41. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 43. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 45. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 46. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 47. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 48. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 49. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 50. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 54. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 55. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 58. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 65. ALKERMES: COMPANY SNAPSHOT
TABLE 66. ALLERGAN: COMPANY SNAPSHOT
TABLE 67. ALLERGAN: OPERATING SEGMENTS
TABLE 68. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 69. LILLY: COMPANY SNAPSHOT
TABLE 70. LILLY: OPERATING SEGMENTS
TABLE 71. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 72. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 73. LUNDBECK: COMPANY SNAPSHOT
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. PFIZER: COMPANY SNAPSHOT
TABLE 77. PFIZER: OPERATING SEGMENTS
TABLE 78. SAGE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 79. TEVA: OPERATING SEGMENTS
TABLE 80. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 02. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 03. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 04. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR PANIC DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 06. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER DEPRESSIVE DISORDER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. GLOBAL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 08. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)
TABLE 09. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2016-2023 ($MILLION)
TABLE 13. ANTI-DEPRESSANT DRUGS MARKET REVENUE FOR OTHER PRODUCT TYPE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 14. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 19. U.S. ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 20. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 21. CANADA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 22. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 23. MEXICO ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 24. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 25. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 26. EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 28. GERMANY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 29. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 30. FRANCE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 31. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 32. UK ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 33. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 34. ITALY ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 35. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 36. SPAIN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 37. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 38. REST OF EUROPE ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 39. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 41. ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 42. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 43. JAPAN ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 45. CHINA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 46. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 47. AUSTRALIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 48. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 49. INDIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 50. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 51. SOUTH KOREA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 54. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 55. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 56. LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 57. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 58. BRAZIL ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 60. SAUDI ARABIA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 62. SOUTH AFRICA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY DEPRESSIVE DISORDER, 2016-2023 ($MILLION)
TABLE 64. REST OF LAMEA ANTI-DEPRESSANT DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 65. ALKERMES: COMPANY SNAPSHOT
TABLE 66. ALLERGAN: COMPANY SNAPSHOT
TABLE 67. ALLERGAN: OPERATING SEGMENTS
TABLE 68. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 69. LILLY: COMPANY SNAPSHOT
TABLE 70. LILLY: OPERATING SEGMENTS
TABLE 71. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 72. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 73. LUNDBECK: COMPANY SNAPSHOT
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. PFIZER: COMPANY SNAPSHOT
TABLE 77. PFIZER: OPERATING SEGMENTS
TABLE 78. SAGE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 79. TEVA: OPERATING SEGMENTS
TABLE 80. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 04. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 05. MARKET SHARE ANALYSIS, 2016
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. BARGAINING POWER OF SUPPLIERS
FIGURE 08. THREAT OF NEW ENTRANTS
FIGURE 09. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER PRODUCT TYPE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 22. ALKERMES: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ALKERMES: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ALKERMES: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. BRISTOL MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. BRISTOL MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. GLAXOSMITHKLINE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. LUNDBECK: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. LUNDBECK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 42. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. TAKEDA PHARMACEUTICAL: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 01. GLOBAL ANTI-DEPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 04. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 05. MARKET SHARE ANALYSIS, 2016
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. BARGAINING POWER OF SUPPLIERS
FIGURE 08. THREAT OF NEW ENTRANTS
FIGURE 09. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER DEPRESSIVE DISORDER, BY COUNTRY, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTI-DEPRESSANT DRUGS MARKET FOR OTHER PRODUCT TYPE, BY COUNTRY, 2016 & 2023 (%)
FIGURE 22. ALKERMES: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ALKERMES: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ALKERMES: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. BRISTOL MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. BRISTOL MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. GLAXOSMITHKLINE: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. LUNDBECK: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. LUNDBECK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 42. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 43. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. TAKEDA PHARMACEUTICAL: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
